StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead Sciences (GILD) Subsidiary Kite Reports End of Phase 1 ZUMA-3 Results for KTE-X19 at ASCO 2019 Meetings
June 3, 2019 5:52 AM
Kite, a Gilead Company (NASDAQ: GILD) announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Management Changes
Management Comments
Next Articles
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
June 1, 2019 6:00 PM
Kite (GILD) and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta With lenzilumab in R/R DLBCL
May 31, 2019 8:32 AM